Tag: Belatacept

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia BCL2 is an anti-apoptotic protein that allows chronic lymphocytic leukemia cells to survive and a promising pharmacologic target for relapsed chronic lymphocytic leukemia. Previously, drugs like navitoclax showed efficacy to the same target but cross-reacted with other proteins and caused thrombocytopenia....
1. Seven years after transplantation, patient and kidney graft survival and function were significantly higher with belatacept than cyclosporine based immunosuppressants. 2. The cumulative frequencies of serious adverse events were similar across both belatacept and cyclosporine groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Renal transplant immunosuppressive therapies usually include calcineurin-inhibitors, like...